NeoPharm Financials
092730 Stock | KRW 12,000 90.00 0.74% |
NeoPharm |
Understanding current and past NeoPharm Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of NeoPharm's financial statements are interrelated, with each one affecting the others. For example, an increase in NeoPharm's assets may result in an increase in income on the income statement.
Please note, the presentation of NeoPharm's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, NeoPharm's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of NeoPharm's management manipulating its earnings.
NeoPharm Stock Summary
NeoPharm competes with MegaStudyEdu, DongKook Pharmaceutical, COWELL FASHION, and MegaStudy. ,Ltd. manufactures and sells skin care products in Korea and internationally. ,Ltd. was founded in 2000 and is headquartered in Daejeon, South Korea. Neopharm is traded on Korean Securities Dealers Automated Quotations in South Korea.Instrument | Korea Stock View All |
Exchange | KOSDAQ |
ISIN | KR7092730001 |
Business Address | 309-8, Techno 2-ro, |
Sector | Personal Products |
Industry | Consumer Staples |
Benchmark | Dow Jones Industrial |
Website | www.neopharm.co.kr |
Phone | 82 4 2863 0038 |
Currency | KRW - South Korean Won |
You should never invest in NeoPharm without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of NeoPharm Stock, because this is throwing your money away. Analyzing the key information contained in NeoPharm's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
NeoPharm Key Financial Ratios
NeoPharm's financial ratios allow both analysts and investors to convert raw data from NeoPharm's financial statements into concise, actionable information that can be used to evaluate the performance of NeoPharm over time and compare it to other companies across industries.Return On Equity | 13.82 | |||
Return On Asset | 0.11 | |||
Target Price | 36000.0 | |||
Number Of Employees | 106 | |||
Beta | 1.11 |
NeoPharm Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining NeoPharm's current stock value. Our valuation model uses many indicators to compare NeoPharm value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across NeoPharm competition to find correlations between indicators driving NeoPharm's intrinsic value. More Info.NeoPharm LTD is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers reporting about 0.01 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for NeoPharm LTD is roughly 129.52 . Comparative valuation analysis is a catch-all model that can be used if you cannot value NeoPharm by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for NeoPharm's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.NeoPharm LTD Systematic Risk
NeoPharm's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. NeoPharm volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was one with a total number of output elements of sixty. The Beta measures systematic risk based on how returns on NeoPharm LTD correlated with the market. If Beta is less than 0 NeoPharm generally moves in the opposite direction as compared to the market. If NeoPharm Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one NeoPharm LTD is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of NeoPharm is generally in the same direction as the market. If Beta > 1 NeoPharm moves generally in the same direction as, but more than the movement of the benchmark.
NeoPharm December 18, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of NeoPharm help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of NeoPharm LTD. We use our internally-developed statistical techniques to arrive at the intrinsic value of NeoPharm LTD based on widely used predictive technical indicators. In general, we focus on analyzing NeoPharm Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build NeoPharm's daily price indicators and compare them against related drivers.
Downside Deviation | 2.78 | |||
Information Ratio | 0.0481 | |||
Maximum Drawdown | 13.31 | |||
Value At Risk | (4.40) | |||
Potential Upside | 5.61 |
Complementary Tools for NeoPharm Stock analysis
When running NeoPharm's price analysis, check to measure NeoPharm's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NeoPharm is operating at the current time. Most of NeoPharm's value examination focuses on studying past and present price action to predict the probability of NeoPharm's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NeoPharm's price. Additionally, you may evaluate how the addition of NeoPharm to your portfolios can decrease your overall portfolio volatility.
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges |